Close
CDMO Safety Testing 2026
Novotech

Drug Research

Inside Cryopreservation: Key Steps and Scientific Insights

It may sound like science fiction to the layperson, but cryopreservation is here, and itโ€™s bridging the gap between whatโ€™s medically possible today and the potential of future technologies. This technology sits at the intersection of biotechnology, medicine and...

ICON Advarra Partnership Builds Research-Ready Trial Model

ICON, a world-leading clinical research organisation, has formalised a definitive partnership agreement with Advarra to introduce a new research-ready trial model designed to reshape how clinical trials are conducted. The collaboration brings together ICONโ€™s global clinical trial solutions with...

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with a fresh wave of capital deployment, underscoring the countryโ€™s growing role in global pharmaceutical strategy. The company confirmed a Novartis China investment exceeding 3.3 billion Chinese yuan (roughly $480 million),...

Egypt-Takeda Pharmaceutical Cooperation Boosts R&D Push

Egypt is stepping up its push to reinforce its pharmaceutical research landscape by deepening pharmaceutical cooperation with Takeda Pharmaceutical Company, aligning with a wider national agenda to strengthen healthcare capabilities and drug development infrastructure. In this context, the Egyptian Drug...

Online Medicine in India and Ganaton Total in Digestive Care

Online medicine delivery in India has seen significant growth as patients look for convenient yet reliable access to prescribed treatments. With chronic digestive disorders on the rise, many physicians prescribe combination therapies such as Ganaton Total to manage complex...

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure by deploying more than 2,100 NVIDIA chips, strengthening its computational capabilities to accelerate drug and diagnostics development. The move, centred on a large-scale Roche AI factory, reflects the companyโ€™s ongoing...

Enhertu Priority Review in HER2-Positive Early Breast Cancer

The supplemental Biologics License Application - sBLA for Enhertu - trastuzumab deruxtecan by AstraZeneca and Daiichi Sankyo has been accepted as well as granted Priority Review in the U.S. when it comes to the treatment of adult patients with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป